Zoetis Inc. (NYSE:ZTS) is a top pet stock to buy according to hedge funds. Barclays reaffirmed a Hold rating with a $136.00 price target after Zoetis reported $2.4 billion in revenue for fiscal Q4 2025, a 3% growth from 2024. Full year 2025 revenue was $9.5 billion, up 2% from 2024. Net income for the year was $2.7 billion. Zoetis focuses on animal health products globally, with operations in the United States and internationally, offering vaccines, medicines, genetic tests, and more for various species.

If you’re considering Zoetis as an investment, other AI stocks may offer greater upside potential with less downside risk. Explore a free report on the best short-term AI stock for more opportunities. For more investment ideas, check out “30 Stocks That Should Double in 3 Years” and “11 Hidden AI Stocks to Buy Right Now.” This article is originally published on Insider Monkey.

Read more at Yahoo Finance: Barclays Remains a Hold on Zoetis Inc. (ZTS)